News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer.

This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer.

The top stories:

Partners launch $25m initiative to develop Parkinson’s treatments

SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson’s disease (PD).

Starget secures $5.1m for clinical trial of targeted cancer therapy

Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation.

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease.

Oversubscribed $200m private placement for gene therapy company

Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million.

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease.